SCHEMBL4933063

SCHEMBL4933063

CCOC(=O)c1[nH]c2ccc(NS(=O)(=O)c3ccc(C(C)(C)C)cc3)cc2c1-c1cccc(C(F)(F)F)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 3/20 0.51
BRD4 O60885 1/20 0.48
ALDH1A1 P00352 2/20 0.45
HPGD P15428 2/20 0.45
XBP1 P17861 2/20 0.45
CYP1A2 P05177 2/20 0.45
CYP2C19 P33261 2/20 0.45
TP53 P04637 6/20 0.44
LMNA P02545 5/20 0.44
MAPT P10636 5/20 0.44
THRB P10828 2/20 0.44
SERPINE1 P05121 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
FFAR1 O14842 1/20 0.43
CDK1 P06493 1/20 0.43
CCNB1 P14635 1/20 0.43
CCNA2 P20248 1/20 0.43
CDK2 P24941 1/20 0.43
CDK7 P50613 1/20 0.43
CCNH P51946 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4929144 0.91 HIF1A (0.52) HIF1ABRD4ALDH1A1HPGDXBP1
SCHEMBL4929352 0.91 HIF1A (0.54) HIF1ABRD4ALDH1A1HPGDXBP1
SCHEMBL4586922 0.90 ALDH1A1 (0.56) HIF1ABRD4ALDH1A1HPGDXBP1
SCHEMBL4931705 0.89 ALDH1A1 (0.55) HIF1ABRD4ALDH1A1HPGDXBP1
SCHEMBL4931881 0.89 HIF1A (0.51) HIF1ABRD4ALDH1A1HPGDXBP1
Dimethylamine SCHEMBL4923606 0.88 ALDH1A1 (0.55) HIF1ABRD4ALDH1A1HPGDXBP1
SCHEMBL3943963 0.88 BRD4 (0.52) BRD4ALDH1A1XBP1CYP1A2CYP2C19
SCHEMBL3942138 0.87 BRD4 (0.47) HIF1ABRD4XBP1TP53LMNA
SCHEMBL4922707 0.87 HIF1A (0.56) HIF1ABRD4ALDH1A1HPGDXBP1
SCHEMBL4922832 0.85 HIF1A (0.51) HIF1ABRD4ALDH1A1HPGDXBP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080004268-A1 INHIBITORS OF SOLUBLE ADENYLATE CYCLASE NGUYEN DUY 2008-01-03 US disclosed
US-20060074084-A1 Inhibitors of soluble adenylate cyclase BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2006-04-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004268-A1 INHIBITORS OF SOLUBLE ADENYLATE CYCLASE ADCY1, ADCY2, ADCY5 HIF1A 1888/4885BRD4 3928/4885ALDH1A1 268/4885
US-20060074084-A1 Inhibitors of soluble adenylate cyclase ADCY1, ADCY2, ADCY5 HIF1A 1888/4885BRD4 3928/4885ALDH1A1 268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.